Navigation Links
Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
Date:3/28/2011

EMERYVILLE, Calif., March 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced its plans to expand the Phase 3 European clinical trial FOCUS, which is evaluating the efficacy and tolerability of carfilzomib, a selective next-generation proteasome inhibitor. The FOCUS trial is designed to support the registrational filing with the European Medicines Agency (EMA) in patients with relapsed and refractory myeloma.  

The FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) trial modification includes two key enhancements to the study: changing the primary end point to overall survival (OS) from progression-free survival (PFS) and correspondingly increasing patient enrollment to 300 from 84.  These modifications are supported by overall survival data from the Phase 2b 003-A1 study evaluating single-agent carfilzomib in patients with relapsed and refractory multiple myeloma announced at the American Society of Hematology (ASH) meeting in December 2010.  The company expects to review these data with the EMA and is moving forward with plans to do so.

"Given the encouraging carfilzomib data reported to date, including the 003-A1 survival data, Onyx decided to make this change to demonstrate a potential mortality benefit for carfilzomib," said Ted Love, M.D., executive vice president, research and development and technical operations at Onyx.  "We plan to upsize the trial at the currently active sites by leveraging the momentum we are seeing in enrollment as well as by adding additional sites, as appropriate."

Focus Trial Design

As modified, the Phase 3 FOCUS study will be a randomized 300-patient trial evaluating carfilzomib versus best supportive care of low dose steroids plus cytoxan (optional), in patients with relapsed and refractory multip
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
2. VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
5. Endo Pharmaceuticals Appoints Dr. David Nash to Board of Directors
6. Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
7. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
8. MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
11. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Clintrax ... services located in Raleigh, NC ... Evans as Vice President of Administration. ... will oversee all corporate processes, including their alignment ... Clintrax Global, Brad worked as an HR executive, ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
(Date:8/20/2014)... Calif. , Aug. 20, 2014 /PRNewswire-iReach/ -- ... the transformative collaboration between the school,s bioengineering department ... part of the Intel® Software Academic Program, UCSD,s ... sciences and the human body.  ... The study exhibits the work of Dr. ...
(Date:8/19/2014)... August 19, 2014 Shimadzu Scientific ... systems, Prominence-i and Nexera-i, adding to the company’s ... excellent functionality, an intuitive operating environment, and full ... more efficient workflow for conventional to ultra-high-speed analysis. ... intuitive and intelligent design so users can begin ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
... , ,MADISON If location is everything, then 5Nines ... wholly owned subsidiary of Matador Consulting , located at ... shares a wall with a major Internet bandwidth provider, ... Norlights point of presence (POP) has created advantages for its ...
... Clinics officers discuss security challenges , ,MADISON The ... lists each patient and their condition is a familiar scene ... privacy? , ,Balancing the best interest of the patient but ... it was the topic of a lecture given by ...
... Safety and Information Technology is a national priority ... budget, technology and finance at the U.S. Department of ... PhD, FACMI, and senior advisor of the National Health ... the Digital Healthcare Conference being held June 22-23, ...
Cached Biology Technology:5Nines Data Services: downtown Madisons new data center 2The challenges of maintaining patient privacy and delivering secure clinical information 2The challenges of maintaining patient privacy and delivering secure clinical information 3U.S. Health and Human Services officials to speak at the Digital Healthcare Conference 2
(Date:8/21/2014)... (ANU) team has successfully replicated one of the crucial ... powered by sunlight which could manufacture hydrogen as a ... It is an exciting prospect to use them to ... Dr Kastoori Hingorani, from the ARC Centre of Excellence ... Biology. , Hydrogen offers potential as a zero-carbon replacement ...
(Date:8/20/2014)... 2014 George E. Fox, a John and Rebecca Moores ... (UH), was named a fellow in the International Society for ... Fox is one of four members two from the ... as fellows in 2014. Fellows are elected every three years, ... 500 members from more than 20 countries, the ISSOL includes ...
(Date:8/20/2014)... University of Tennessee, Knoxville, research finds life can persist ... professor was part of a team that examined waters ... Antarctic ice sheet and found the extreme environment supports ... by Jill Mikucki and her colleagues has implications for ... in the solar system. The findings are published in ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2UH professor named fellow by International Astrobiology Society 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... rare genetic disease, genetics researchers have identified a novel ... human development, potentially in cases of mental retardation and ... two genes that contribute to Cornelia deLange syndrome (CdLS), ... in 10,000 children. The disease varies from milder to ...
... an enhanced long-term memory, researchers report in the April ... Cell Press. These findings point to a potential target ... loss, according to the researchers. , The researchers studied ... memory-blocking protein. Animals that carry a defective version of ...
... an old mine in California is proving to be a ... how bacterial communities exist in nature. , A letter published ... possible to follow what microorganisms are doing in their natural ... The technique, utilized in a microbial community thriving in battery ...
Cached Biology News:Gene found for rare disorder may reveal new pathway in mental retardation 2Mutation improves memory, may lead to memory-enhancing pill 2Mutation improves memory, may lead to memory-enhancing pill 3Mine runoff continues to provide clues to microbial diversification 2Mine runoff continues to provide clues to microbial diversification 3
... Taq DNA Polymerase is a thermostable recombinant ... in primer extension and other molecular biology ... which provides easy and quick identification of ... allows confirmation of complete mixing. The inert ...
... The EnzChek Lysozyme Assay Kit (E-22013) ... measure levels of lysozyme,activity in solution. ... down to 20 U/mL (Figure 1). ... lysodeikticus cell,walls, which are labeled to ...
RNA oligomers from 10 to 50 bases purified by PAGE and MS-checked. RNAs are supplied dried and fully deprotected....
... (Cap Analog) is used for the synthesis ... vitro transcription reactions. Substitution of cap analog ... in an in vitro transcription reaction results ... into a large fraction of the transcripts. ...
Biology Products: